Navigation Links
AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
Date:2/11/2008

Clinical Data Presented at the 66th Annual Meeting of the American Academy

of Dermatology

FREEPORT, N.Y., Feb. 11 /PRNewswire/ -- AGI Dermatics clinical research indicates that the ability of bicyclic monoterpene diols (BMTds) to reduce collagenese MMP-1 secretion and increase collagen production is dependent on the TNF-a signaling in the fibroblasts. The data was presented at the Poster Session at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio.

"Our prior research showed that BMTds increase collagen gene expression and protein production while decreasing MMP-1 secretion," said Daniel Yarosh, PhD, President, AGI Dermatics. "This study gives us insight into the cellular communication that allows BMTds to work so effectively and efficiently in treating photodamaged skin."

BMTds, a class of compounds known to increase nitric oxide levels, were recently reported to play a major role in collagen synthesis. AGI scientists questioned whether the transmission of BMTd factors were influenced by the role of Interleukin-6 (IL-6) and TNF-A in regulating collagen 1 and MMP-1 secretions.

In earlier studies of BMTds, AGI scientists observed a linear increase in BMTd concentrations and secretion of interleukin-6 (IL-6), a multi-functional cytokine that mediates a wide variety of functions in cells, promotes cell proliferation and regulates gene expression. By blocking the IL-6 signaling with a neutralizing IL-6 antibody, studies showed a concomitant increase in MMP-1 and a reduction in collagen 1. The effect of the neutralizing antibody, however, was gradually overcome by increasing BMTd concentrations, indicating that IL-6 is not involved in the transmission of the BMTd effect. Results indicated a linear decrease in MMP-1 secretion and an increase in collagen production, two key components in treatment of photoaged skin.

Similarly, blocking TNF-a signaling in the fibroblasts with a TNF-a neutralizing antibody also increases MMP-1 and decreases collagen secretion. However, blocking TNF-a signaling also blocks the BMTd effect.

AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Pinoxide, an exclusive and patented blend of bicyclic monoterpene diols, is formulated in Remergent Microcirculation Therapy.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Indonesia , Jan. 17, 2017  With an annual growth ranging from 6% ... success. CPhI SEA (Jakarta International Expo, March 22-24, 2017) serves the industry ... What,s new at CPhI SEA 2017? Investment Forum ... Distributors, network Richer conference content Enhanced business matchmaking ... ...
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, ... for cell and advanced therapies , has announced ... biopharmaceutical company developing "tumor starvation" treatments for acute ... needs. Under the agreement, Invetech will develop systems ... on Erytech,s proprietary ERYCAPS technology platform, which uses ...
(Date:1/18/2017)... MIAMI , January 18, 2017 ... announced the company plans to publish an online ... the Company,s preliminary sales forecast for 2017. Management ... Company,s trialing ninety-day record sales performance from its ... recently announced entry into the Cannabis sector ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology has been selected ... , Each year, Pink Elephant recognizes a new product or service developed ... specific business problem or opportunity. The award highlights original innovations that were released in ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... 2017 , ... Medic-CE , a Career Step company ... released four new continuing education courses as part of its Code3 CME Virtual ... classroom and meet the requirements of the National Continued Competency Program (NCCP), the ...
(Date:1/17/2017)... ... , ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum ... Design Challenge , the Cradle to Cradle Products Innovation Institute has announced. ... to run through early 2018. The challenges are presented by the Institute in partnership ...
Breaking Medicine News(10 mins):